Articles Tagged With:
-
Can You Make ‘Flat’ Basal Insulin ‘Flatter?’
For patients incurring problematic episodes of hypoglycemia, an insulin that provides even “flatter” plasma levels may provide an advantage.
-
FDA Actions
The FDA has approved two drugs for the treatment of diarrhea-predominant irritable bowel syndrome.
-
Addition of Ezetimibe to Simvastatin May Improve CV Outcomes
A new study suggests the addition of ezetimibe to simvastatin may improve cardiovascular outcomes in patients with acute coronary syndrome, although the effect is modest.
-
Beta-blockade Use in Non-cardiac Surgery Patients
Perioperative beta-blockade appears to be beneficial for patients with high cardiac risk factors undergoing NCS, but it increased the risk of death in those with no cardiac risk factors.
-
Compliance Mentor - June 2015
-
Spring clean IRB reviews by focusing on review criteria
As IRB workloads shift to summer schedules, it’s a good time to assess whether boards are staying on mission focus, an IRB chair suggests.
-
Here are a few risk-benefit examples
As IRBs debate and consider how to assess risks and benefits in research, here are a couple of examples of cases where IRBs made controversial and sometimes opposing decisions.
-
Dig deep when analyzing risks and benefits
When IRBs and investigators deal with risks, they should identify reasonably foreseeable risks and have reasonable precautions to prevent harm.
-
Top IRB findings during accreditation site visits
IRBs and human subjects research protection programs continue to find concerns during site visits in the accreditation process.
-
AAHRPP findings reveal issues IRBs need to address
Each year, human subjects protection programs worldwide prepare for accreditation, making changes and improving processes. Which problems crop up most frequently?